Imagion Biosystems Limited has lodged Appendix 3X, Initial Director’s Interest Notice, with the Australian Securities Exchange.
View the Initial Director’s Interest Notice.
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance